Targeting Apoptotic Pathways in Acute Myeloid Leukaemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Acute Myeloid Leukaemia (AML) remains a significant challenge with poor patient outcomes.
• Recent advances in understanding AML's molecular landscape have spurred targeted drug development.
• Aberrant programmed cell death pathways are implicated in AML pathobiology.

Purpose of the Study:

• To review preclinical and clinical evidence for BCL-2 targeting drugs in AML.
• To highlight Venetoclax as the most advanced BCL-2 inhibitor in AML.
• To discuss rational combinations, ongoing trials, and biomarkers for Venetoclax therapy.

Main Methods:

• Review of preclinical studies on BCL-2 inhibitors in AML models.
• Analysis of clinical trial data for Venetoclax in AML patients.
• Identification and synthesis of research on combination therapies and response biomarkers.

Main Results:

• Drugs targeting the BCL-2 family of anti-apoptotic proteins show therapeutic potential in AML.
• Venetoclax has demonstrated efficacy and is the leading BCL-2 inhibitor in clinical development for AML.
• Early phase trials have identified potential biomarkers predictive of response to Venetoclax.

Conclusions:

• Targeting BCL-2 represents a promising therapeutic strategy for Acute Myeloid Leukaemia.
• Venetoclax, in combination with other agents, offers new hope for AML patients.
• Further research and clinical trials are essential to optimize Venetoclax-based therapies and identify patient subgroups most likely to benefit.